SGMO earnings call for the period ending March 31, 2020.
News & Analysis: Sangamo Therapeutics
Which stock wins in a battle between these two clinical-stage biotechs?
Which of these two gene-editing companies is the better investment?
With the coronavirus pandemic on everyone's mind, these three promising stocks have stayed under the radar.
With valuations cut in half, investors should consider these promising gene-editing companies.
The biotech secured another big partner.
SGMO earnings call for the period ending December 31, 2019.
The partnership would focus on developing treatments for neurological diseases.
Both of these gene editing stocks have a lot going for them, but which one is better?
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.